SBI.L

SourceBio International plc
SourceBio Intl PLC - Notice of Results
19th August 2022, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5264W
SourceBio International PLC
19 August 2022
 

SourceBio International plc

('SourceBio', the 'Company' or the 'Group')

 

 

Notice of Half Year Results

and

Investor presentation

 

SourceBio International plc (AIM: SBI), a leading international provider of integrated state-of-the-art laboratory services, announces that its unaudited half year results for the six months ended 30 June 2022 are expected to be released on 8 September 2022.

 

Investor Presentation

Jay LeCoque, Executive Chairman, and Tony Ratcliffe, Chief Financial Officer, will provide a live presentation on the Half Year Results via the Investor Meet Company platform on the following day, 9th September 2022, at 9:30am BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet SourceBio International plc via:

https://www.investormeetcompany.com/sourcebio-international-plc/register-investor

Investors who already follow SourceBio International plc on the Investor Meet Company platform will automatically be invited.

 

Contacts: 

SourceBio International plc                         

www.sourcebiointernational.com

Jay LeCoque, Executive Chairman

Via Walbrook PR

Tony Ratcliffe, Chief Financial Officer




Liberum (Nominated Advisor and Broker)

Tel: 020 3100 2000

Richard Lindley / William Hall / Miquela Bezuidenhoudt




Walbrook PR Limited

Tel: 020 7933 8780 or sourcebio@walbrookpr.com

Paul McManus / Sam Allen

Mob: 07980 541 893 / 07502 558 258 

 

 

About SourceBio International plc www.sourcebiointernational.com

SourceBio is a leading international provider of integrated state-of-the-art laboratory services with clients in the pharmaceutical, healthcare, clinical, drug development and life sciences research industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four business units:

 

●

Healthcare Diagnostics - Histopathology cancer screening, including Digital Pathology and clinical diagnostic services for the NHS and private healthcare providers across the UK

●

Genomics - DNA sequencing services and Precision Medicine offering for pharmaceutical and biotechnology industries, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America

●

Stability Storage Controlled environmental storage services and laboratory equipment validation services for pharmaceutical industry in the UK, Ireland and North America

●

Infectious Disease Testing - A range of COVID-19 testing services for commercial enterprises, private healthcare groups and the NHS, including PCR testing under ISO 15189 accreditation.

 

More details on Group operations can be found here: www.sourcebioscience.com

 

SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORQVLFFLVLBBBB ]]>
TwitterFacebookLinkedIn